Regulus Therapeutics Inc. (RGLS): Price and Financial Metrics
RGLS Price/Volume Stats
| Current price | $2.22 | 52-week high | $3.79 |
| Prev. close | $2.26 | 52-week low | $1.08 |
| Day low | $2.22 | Volume | 91,800 |
| Day high | $2.29 | Avg. volume | 2,452,532 |
| 50-day MA | $2.14 | Dividend yield | N/A |
| 200-day MA | $1.56 | Market Cap | 145.33M |
RGLS Stock Price Chart Interactive Chart >
Regulus Therapeutics Inc. (RGLS) Company Bio
Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. The company was founded in 2007 and is based in San Diego, California.
Latest RGLS News From Around the Web
Below are the latest news stories about REGULUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RGLS as an investment opportunity.
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November 29, at 10:25 a.m. ET. |
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2023. |
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. |
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, that it will advance to the third cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months. |
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. |
RGLS Price Returns
| 1-mo | -21.97% |
| 3-mo | 76.19% |
| 6-mo | 77.60% |
| 1-year | 64.44% |
| 3-year | -84.79% |
| 5-year | -79.82% |
| YTD | 73.44% |
| 2023 | -6.57% |
| 2022 | -56.51% |
| 2021 | -76.67% |
| 2020 | 51.69% |
| 2019 | -4.30% |
Continue Researching RGLS
Here are a few links from around the web to help you further your research on Regulus Therapeutics Inc's stock as an investment opportunity:Regulus Therapeutics Inc (RGLS) Stock Price | Nasdaq
Regulus Therapeutics Inc (RGLS) Stock Quote, History and News - Yahoo Finance
Regulus Therapeutics Inc (RGLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...